Silicon-containing compound for resistance to hepatitis C virus infection

A compound of Formula I, a pharmaceutically acceptable salt, a tautomer, a stereoisomer or a deuteride thereof, or a mixture thereof:

• wherein:
• R1 and R2 are each independently selected from the group consisting of hydroxyl, alkyl, alkoxy and aryl, or R1 and R2 are joined to form a silicon-containing saturated aliphatic ring containing 1, 2 or 3 silicon atoms;
• R3, R4, R5 and R6 are each independently selected from the group consisting of hydrogen and halogen;
• X is selected from the group consisting of the following groups:
• Y is selected from the group consisting of the following groups:
• R7 and R8 are each independently selected from the group consisting of —CH(alkyl)(alkoxy), —CH(alkyl)2, —CH(alkoxy)2, —C(alkyl)2(alkoxy), —C(alkyl)(alkoxy)2, —C(alkyl)3 and —C(alkoxy)3;
• R9 and R10 are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, and alkoxyalkyl;
• each of Ra and Rb is independently selected from the group consisting of hydrogen, halogen, and alkyl;
• each m is independently selected from the group consisting of 0, 1, 2, 3, and 4;
• and
• n is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, and 8.